Skip Navigation

JNCI Journal of the National Cancer Institute 1999 91(7):641-643; doi:10.1093/jnci/91.7.641
© 1999 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by de Cremoux, P.
Right arrow Articles by Soussi, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by de Cremoux, P.
Right arrow Articles by Soussi, T.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 91, No. 7, 641-643, April 7, 1999
© 1999 Oxford University Press

BRIEF COMMUNICATION

p53 Mutation as a Genetic Trait of Typical Medullary Breast Carcinoma

Patricia de Cremoux, Anne Vincent Salomon, Stephane Liva, Rémi Dendale, Brigitte Bouchind'homme, Emmanuel Martin, Xavier Sastre-Garau, Henri Magdelenat, Alain Fourquet, Thierry Soussi

Affiliations of authors: P. de Cremoux (Department of Pathology and Universite Paris 7), A. V. Salomon, B. Bouchind'homme, X. Sastre-Garau (Department of Pathology), S. Liva, E. Martin (Department of Translational Research), R. Dendale, A. Fourquet (Department of Radiotherapy), H. Magdelenat (Departments of Pathology and Translational Research), T. Soussi (Unité Mixte de Recherche 218, Centre National de la Recherche Scientifique), Institut Curie, Paris, France.

Correspondence to: Patricia de Cremoux, M.D., Ph.D., Department of Pathology, Institut Curie, 26 rue d'Ulm, 75248, Paris cedex 05, France (e-mail: Patricia.De-Cremoux@curie.fr).

Medullary carcinoma is a poorly differentiated breast cancer tumor with a high histologic grade and a paradoxically good prognosis. It accounts for only 5% of all breast cancers (1-3). Thus far, only histologic criteria are used to define this tumor type; no genetic characteristics have been identified. An alteration in the p53 gene (also known as TP53) is found in 20%-40% of invasive breast cancers, but its status in medullary breast cancer is poorly documented. Immunochemical detection of a stable mutant p53 in nuclei of tumor cells is the most convenient assay, but the correlation of the results from such an assay with results from molecular analysis, such as sequencing, is not totally in agreement (4). The frequency of p53 mutations in breast cancer is around 20%, but immunohistochemical analysis detects p53 accumulation in 30%-40% of tumors (5,6).

In the . . . [Full Text of this Article]

NOTES

REFERENCES


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Cancer Res.Home page
E. Manie, A. Vincent-Salomon, J. Lehmann-Che, G. Pierron, E. Turpin, M. Warcoin, N. Gruel, I. Lebigot, X. Sastre-Garau, R. Lidereau, et al.
High Frequency of TP53 Mutation in BRCA1 and Sporadic Basal-like Carcinomas but not in BRCA1 Luminal Breast Tumors
Cancer Res., January 15, 2009; 69(2): 663 - 671.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
M. Lacroix, R.-A. Toillon, and G. Leclercq
p53 and breast cancer, an update.
Endocr. Relat. Cancer, June 1, 2006; 13(2): 293 - 325.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
F. Bertucci, P. Finetti, N. Cervera, E. Charafe-Jauffret, E. Mamessier, J. Adelaide, S. Debono, G. Houvenaeghel, D. Maraninchi, P. Viens, et al.
Gene Expression Profiling Shows Medullary Breast Cancer Is a Subgroup of Basal Breast Cancers.
Cancer Res., May 1, 2006; 66(9): 4636 - 4644.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
A. Ayyanan, G. Civenni, L. Ciarloni, C. Morel, N. Mueller, K. Lefort, A. Mandinova, W. Raffoul, M. Fiche, G. P. Dotto, et al.
Increased Wnt signaling triggers oncogenic conversion of human breast epithelial cells by a Notch-dependent mechanism
PNAS, March 7, 2006; 103(10): 3799 - 3804.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. Olivier, A. Langerod, P. Carrieri, J. Bergh, S. Klaar, J. Eyfjord, C. Theillet, C. Rodriguez, R. Lidereau, I. Bieche, et al.
The Clinical Value of Somatic TP53 Gene Mutations in 1,794 Patients with Breast Cancer
Clin. Cancer Res., February 15, 2006; 12(4): 1157 - 1167.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
L. Orlando, G. Renne, A. Rocca, G. Curigliano, M. Colleoni, G. Severi, G. Peruzzotti, S. Cinieri, G. Viale, G. Sanna, et al.
Are all high-grade breast cancers with no steroid receptor hormone expression alike? The special case of the medullary phenotype
Ann. Onc., July 1, 2005; 16(7): 1094 - 1099.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
M. H. Hansen, H. V. Nielsen, and H. J. Ditzel
Translocation of an Intracellular Antigen to the Surface of Medullary Breast Cancer Cells Early in Apoptosis Allows for an Antigen-Driven Antibody Response Elicited by Tumor-Infiltrating B Cells
J. Immunol., September 1, 2002; 169(5): 2701 - 2711.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. Alsner, M. Yilmaz, P. Guldberg, L. L. Hansen, and J. Overgaard
Heterogeneity in the Clinical Phenotype of TP53 Mutations in Breast Cancer Patients
Clin. Cancer Res., October 1, 2000; 6(10): 3923 - 3931.
[Abstract] [Full Text]

Home page
 JNCI J Natl Cancer InstHome page
M. Esteller, J. M. Silva, G. Dominguez, F. Bonilla, X. Matias-Guiu, E. Lerma, E. Bussaglia, J. Prat, I. C. Harkes, E. A. Repasky, et al.
Promoter Hypermethylation and BRCA1 Inactivation in Sporadic Breast and Ovarian Tumors
J Natl Cancer Inst, April 5, 2000; 92(7): 564 - 569.
[Abstract] [Full Text] [PDF]